I have heard it all my life: “Health is Wealth.” It is something our mothers and grandmothers said, something you would see printed on posters at clinics or in schoolbooks. And yet, for many women in Bangladesh, that simple truth feels out of reach. Ask any woman around you, and chances are she has a story of symptoms ignored or being told it is “just stress” or “hormones.” Whether it is persistent fatigue, menstrual complications, or unexplained aches, the pattern is strikingly common. These stories are not just personal. They reflect a larger problem—one that affects families, workplaces, and the economy at large. In Bangladesh, where women play a central role in both the home and the labour force, poor health doesn’t just hurt individuals—it holds the entire country back. And while we often talk about women’s empowerment in terms of education or employment, the conversation around health, especially women’s health, remains far too quiet. Recent research shows that targeted investments in women’s health could unlock trillions of dollars in productivity and prevent billions in avoidable healthcare costs. Investing early and equitably can boost economic output, improve workplace participation, and ensure better health outcomes across generations.
The Science: Why Women Need Diverse Healthcare Approaches
Historically, medical studies focused nearly solely on male individuals. Women were mostly excluded from clinical studies until the 1990s. Even today, despite the fact that women account for nearly half of all trial participants, several therapeutic fields still lack proportional representation. One 2022 review of over 1,400 trials discovered that female inclusion frequently lagged far behind national disease prevalence statistics. This is significant since women are naturally different. They experience and display symptoms of diseases in ways that differ from the masculine norm. Cardiovascular illness is a prime illustration. For years, standards were based on data collected from men despite the fact that women have specific risk factors and symptoms. Today, cardiovascular disease remains the leading cause of death in women, with mortality rates increasing among younger women, especially those who enter early menopause.
The pattern holds across other conditions, from stroke to autoimmune disorders to depression. Women have unique hormonal cycles, respond differently to drugs, and are more prone to certain illnesses. Without data that accurately reflects these differences, diagnosis is delayed, treatments are ineffective, and long-term health outcomes worsen. Furthermore, mental health conditions like anxiety and depression are more prevalent among women yet often lack tailored interventions or gender-specific support frameworks. Pregnancy and menopause are also severely under-researched despite impacting every woman at some point. Changes in hormonal profiles across the lifespan create different responses to medication, yet medical protocols often ignore these variations. Even conditions like Alzheimer’s disease, which disproportionately affects women, have received limited gender-specific research attention. As the population ages, failing to understand and address these nuances will have mounting societal and economic costs.
The Economics: Poor Women’s Health is Costing Us Billions
Women are the backbone of both the workforce and the home. Today, more women are working than ever before. They represent over half of college graduates and a growing share of leadership roles. Yet despite their economic contributions, women still face major barriers to full participation due to unaddressed health needs.
Menopause is a striking case study. It affects nearly all women eventually, often during the prime of their careers. Symptoms like sleep disruption, cognitive fog, mood swings, and fatigue often go unsupported—even though they can severely impact performance. Research estimates that menopause-related productivity loss costs the U.S. economy $1.8 billion annually. And that figure doesn’t even include the cost of early retirement, reduced hours, or job changes driven by unmanaged symptoms. Similarly, conditions like endometriosis, fibroids, polycystic ovarian syndrome (PCOS), and postpartum depression cause significant pain and missed work yet receive a fraction of research funding. When health problems are dismissed or untreated, women are more likely to miss days, struggle to perform, or exit the workforce entirely. Women are also the primary caregivers in most families. When they’re unwell, entire households are affected—including children, partners, and elderly relatives. The economic ripple effect is massive, stretching from healthcare costs to productivity losses to broader societal strain. When a woman leaves her job due to poor health, she doesn’t just lose income. Her family may face increased caregiving costs, her employer bears the cost of turnover, and the broader economy suffers from reduced tax revenue and slowed growth. This inefficiency strains both private sector resources and government budgets, creating a burden that could be alleviated with strategic, long-term investment in preventive care and research.
Underinvestment in a High-Return Market
Despite the clear need and the enormous market potential, women’s health remains severely underfunded. Of the billion-dollar investments in the health sector, just a few percentages focus on women’s health. This is a classic case of market inefficiency. Demand is high, the addressable population is half the planet, and early-stage companies in the space are already demonstrating profitability and scalability. In the past five years alone, there have been 35 successful exits from women’s health startups, including IPOs and major acquisitions. Femtech solutions—which span fertility tracking, menstrual care, menopause support, and mental health—are growing rapidly. But this is just the beginning. The women’s health market in USA was worth $41.3 billion in 2023 and is projected to reach $66 billion by 2033. The true value, however, extends far beyond any single market category. Investors are beginning to wake up to the opportunity, but many still underestimate the potential size and depth of this market. Consumer loyalty in the space is typically high, and companies that address real unmet needs often enjoy strong word-of-mouth growth. Moreover, products that empower women to manage their health more effectively tend to have lower churn and longer lifetime value, making them ideal for long-term investment.
A Global Issue Needing Global Solutions
This is not just a problem for high-income countries. In emerging markets, the gaps are even wider and the potential returns even greater. In Bangladesh, for instance, large garment factories implementing basic on-site healthcare for their mostly female workforce saw absenteeism fall and increased productivity.
Whether it’s access to prenatal care, treatment for chronic conditions, or safe maternal health services, low- and middle-income countries face deep challenges—but also opportunities. Telemedicine, community-based care models, and mobile health technologies can bring life-changing solutions to hard-to-reach populations. International collaboration is key. Governments, corporations, and investors must align on funding research, ensuring access, and building infrastructure. Public-private partnerships and policy incentives can fast-track progress. And women must be involved in every level of decision-making, from lab bench to boardroom. Without inclusive leadership, the unique needs of half the population will continue to be marginalised. Organisations like the World Health Organisation and the World Economic Forum have increasingly recognised the importance of women’s health as central to sustainable development. Global policy frameworks are beginning to integrate gender into healthcare strategy, but implementation is uneven. To make real progress, countries must treat gender equity in health as a cornerstone of their economic agendas.
The Ethical Imperative
We cannot ignore the ethical dimension of this issue. Women make up half the population. Their health cannot be secondary, nor should their suffering be normalised. Yet, time and again, conditions that primarily or disproportionately affect women receive less attention, less funding, and fewer tailored treatments. Treating women’s health as a side category leads to worse outcomes for everyone. Clinical trials that don’t represent the full population result in drugs that may not work—or ould even be harmful. Healthcare systems designed without women’s input miss critical needs. Ignoring menopause or maternal mental health means ignoring millions of people at a pivotal time in their lives. Equity in health research, care delivery, and policy isn’t optional—it’s essential for a functioning society. If our systems continue to sideline women’s health, we will continue to experience the economic and social consequences. But if we choose to prioritise it, we set the stage for a more productive, resilient, and just society.
What Needs to Change
Increase Funding: Women-focused research and startups need more capital. Governments should increase grants for sex-specific studies. Investors should recognise the long-term ROI of the femtech space.
Improve Data & Research: Mandate sex-based analysis in clinical trials and ensure transparency in reporting. Expand research into underfunded conditions that uniquely or disproportionately affect women.
Update Workplace Policies: Employers must offer comprehensive women’s health benefits—including menopause, fertility, and maternal care support. Flexible work, paid leave, and accommodations for health needs should be standard.
End the Stigma: From menstruation to menopause, taboo topics prevent women from getting care. Normalise conversations and educate healthcare providers, managers, and policymakers.
Elevate Women’s Voices: Include more women in leadership roles across health, science, and policy. Representation drives more inclusive decision-making and faster progress.
Create Accountability: Track gender health metrics at the national level. Require transparency from pharmaceutical companies, healthcare providers, and insurers on how they serve women. Metrics must inform action.
Women’s health is not a niche market or a special interest. It’s a foundational pillar of any thriving society. The science is clear. The economic case is overwhelming. And the ethical imperative is undeniable. By investing in better healthcare for women—at work, at home, and across every stage of life, we don’t just improve individual outcomes. We strengthen families, grow economies, and build a more equitable future. It’s time to stop asking whether we can afford to prioritise women’s health. The real question is: how can we afford not to?
Author: Anika Tasnim
